Amgen's Parasabiv Rejected by FDA
News Aug 26, 2016
Amgen has announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the New Drug Application (NDA) for Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
The correspondence of a Complete Response Letter means that the FDA has decided that they will not approve Parsabiv in its present form.
Amgen is reviewing the Complete Response Letter, and anticipate a post-action meeting with the FDA later this year to discuss the Complete Response.
Amgen claim that the Complete Response Letter does not impact their regulatory submissions in other regions.
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019